BioInvent International
Develops novel, first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
Description
BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2013-05-24 08:45 |
BioInvent recruits Michael Oredsson as new CEO
|
English | 85.5 KB | ||
| 2013-05-24 08:45 |
BioInvent rekryterar Michael Oredsson som ny VD
|
Swedish | 135.4 KB | ||
| 2013-05-17 15:45 |
Kallelse till extrastämma i BioInvent International AB
|
Swedish | 146.9 KB | ||
| 2013-04-29 14:50 | English | 34.7 KB | |||
| 2013-04-26 16:27 | English | 34.6 KB | |||
| 2013-04-25 12:45 |
BioInvent International AB Annual General Meeting
|
English | 137.8 KB | ||
| 2013-04-25 12:45 |
Årsstämma i BioInvent International AB
|
Swedish | 138.9 KB | ||
| 2013-04-25 08:30 | Swedish | 267.0 KB | |||
| 2013-04-25 08:30 | English | 310.5 KB | |||
| 2013-04-22 08:30 |
BioInvent inleder klinisk studie av läkemedelskandidaten BI-505 i patienter med…
|
Swedish | 138.7 KB | ||
| 2013-04-22 08:30 |
BioInvent initiates clinical trial with BI-505 in smoldering myeloma
|
English | 151.6 KB | ||
| 2013-04-16 16:49 | English | 34.7 KB | |||
| 2013-04-16 08:27 |
Prekliniska data publicerade i Cancer Cell framhåller BI-505 och visar på kraft…
|
Swedish | 157.6 KB | ||
| 2013-04-16 08:27 |
Preclinical data published in Cancer Cell highlight novel antibody BI-505 and p…
|
English | 171.1 KB | ||
| 2013-04-12 16:34 | English | 34.6 KB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioInvent International
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
